PCM
REGN icon

Princeton Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Princeton Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$942K Sell
1,219
-21
-2% -$16.1K 0.26% 52
2025
Q4 		$957K Buy
1,240
+25
+2% +$17K 0.25% 50
2025
Q3 		$683K Sell
1,215
-25
-2% -$14.1K 0.18% 56
2025
Q2 		$651K Buy
1,240
+23
+2% +$12.8K 0.19% 56
2025
Q1 		$772K Sell
1,217
-18
-1% -$12.4K 0.27% 50
2024
Q4 		$880K Sell
1,235
-10
-0.8% -$8.39K 0.27% 46
2024
Q3 		$1.31M Sell
1,245
-39
-3% -$43.4K 0.41% 41
2024
Q2 		$1.35M Buy
1,284
+392
+44% +$380K 0.44% 41
2024
Q1 		$859K Buy
892
+35
+4% +$33.3K 0.31% 53
2023
Q4 		$753K Buy
857
+14
+2% +$11.5K 0.3% 55
2023
Q3 		$694K Hold
843
– – 0.32% 56
2023
Q2 		$606K Buy
843
+85
+11% +$65.5K 0.25% 56
2023
Q1 		$623K Sell
758
-16
-2% -$12.1K 0.27% 60
2022
Q4 		$558K Hold
774
– – 0.25% 67
2022
Q3 		$533K Buy
774
+16
+2% +$10.1K 0.23% 64
2022
Q2 		$448K Hold
758
– – 0.17% 71
2022
Q1 		$529K Sell
758
-16
-2% -$10.1K 0.16% 71
2021
Q4 		$489K Buy
774
+89
+13% +$54.7K 0.14% 76
2021
Q3 		$415K Hold
685
– – 0.13% 79
2021
Q2 		$383K Buy
685
+13
+2% +$6.59K 0.12% 79
2021
Q1 		$318K Buy
+672
New +$327K 0.11% 84
2019
Q4 		– Sell
-265
Closed -$74K – 184
2019
Q3 		$74K Hold
265
– – 0.04% 128
2019
Q2 		$83K Hold
265
– – 0.04% 125
2019
Q1 		$109K Sell
265
-11
-4% -$4.53K 0.06% 114
2018
Q4 		$103K Sell
276
-197
-42% -$72.1K 0.06% 116
2018
Q3 		$191K Sell
473
-2,804
-86% -$1.07M 0.08% 100
2018
Q2 		$1.13M Sell
3,277
-49
-1% -$15.3K 0.49% 39
2018
Q1 		$1.15M Sell
3,326
-358
-10% -$125K 0.51% 40
2017
Q4 		$1.39M Buy
+3,684
New +$1.49M 0.62% 36

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Princeton Capital Management's REGN Position: Q1 2026 in Review

Princeton Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q1 2026, selling an estimated $16.1K and leaving 1,219 shares worth $942K. The position accounts for 0.26% of the portfolio, ranked #52.

Princeton Capital Management first reported a position in REGN in Q4 2017 and has held it in 29 quarters since. The position peaked at $1.39M in Q4 2017. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Princeton Capital Management held 1,219 shares of Regeneron Pharmaceuticals worth $942K as of Q1 2026.
  • Princeton Capital Management sold 21 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.1K.
  • Regeneron Pharmaceuticals made up 0.26% of Princeton Capital Management's portfolio in Q1 2026, its #52 holding.
  • Princeton Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
  • Princeton Capital Management's Regeneron Pharmaceuticals position peaked at $1.39M in Q4 2017.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Princeton Capital Management's 13F filing for Q1 2026, filed 8 May 2026.